Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing Weekly

Investments in hedge funds surged to pre-crisis level: hedge fund news, week 13

Saturday, March 22, 2014

In the week ending 21 March, 2014, eVestment said investments into hedge funds are piling up as inflows surged to pre-financial crisis level; hedge funds and private equity firms have been increasingly looking to invest in shipping; hedge funds’ big bets in General Motor are now reporting losses; hedge funds and venture capitalists have exposures in bitcoin; Pantera Capital invested about $10m in bitcoin exchange Bitstamp; hedge funds have cut their long exposures to the S&P500 back down to a net short while according to other reports hedge fund managers said there is still plenty of money to be made in the stock market. Funds are also said to be wary of betting on rates. Odey Asset bought a $116m stake in Circassia Pharmaceuticals that specializes in treating allergies; ; and Citadel Advisors cranked up its ownership stake in Cincinnati-based bank Fifth Third.

Eric Mindich’s Eton Park Capital Management bought shares in Teekay Corp., General Motors, Allegion, and Air Products & Chemicals; Marathon Asset bets prices will fall in the high-yield, high-risk bond market; the polar vortex has revived interest in gas and power from hedge funds; GoldenTree’s CIO Steven Tananbaum said there is opportunity in Gazprom amidst ongoing turmoil in the Crimean peninsula; and AQR Capital Management disclosed its position in Vodafone Group, Gaming and Leisure Properties, Allegion, Facebook, Omnicom Group, and LSI Corporation.

Hong Kong hedge funds tapped ‘fake’ Alibaba shares ahead of its IPO.

Hedge Fund Research said new hedge fund launches fell to their lowest level in three......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for